WASHINGTON (AP) — Federal regulators say approval of the first generic version of cancer drug Doxil will help resolve a lingering shortage triggered by manufacturing deficiencies.
The shortage of the Johnson & Johnson injectable medication, made under contract by Ben Venue Laboratories, has continued on and off for a few years. It's resulted in rationing, with some patients with ovarian and other cancers getting less-effective care, and disrupted studies testing Doxil against possible new treatments.
The Food and Drug Administration says it's approved a generic version, called doxorubicin, made by Sun Pharma Global FZE. Last February, the FDA authorized temporary importation from India of a brand-name version, called Lipodox, also made by Sun Pharma. It's a subsidiary of an Indian drugmaker.
Meanwhile, J&J continues to seek a contract manufacturer to replace Ben Venue.
Obama's Trip to Paris For Global Warming Summit Sure Emitted a Lot of Greenhouse Gases | Christine Rousselle
Reid: GOP Rhetoric Caused 'Frenzy of Hate,' So Planned Parenthood Probe Must Be Shut Down | Guy Benson
The Worst Gun Ever Made? - Bearing Arms - Calico, Video
Contained? New Report Says There’s ‘Unprecedented’ ISIS Mobilization In The U.S.
5 Reasons I Will Not Vote For Trump If He Is The GOP Nominee | RedState
Why California Environmentalists Hate Water | Human Events
Guy Benson fact-checks Sally Kohn
- What Is Your U.S. Income Percentile Ranking?
Reporter asks Ted Cruz four times: “How do you define amnesty?”